PTGER4 and cancer: Different antiplatelet agents, such as aspirin DG-041 (an EP3 receptor antagonist), and ticagrelor (a P2Y12 receptor antagonist), prevented EMT of cancer cells by inhibiting platelet activation and platelet-derived PGE2 release involved in cancer cell EP4-dependent migration (Guillem-Llobat et al., 2016).